−0.21USD
−6.69 MUSD
129.01 MUSD
17.98 M
About Entrada Therapeutics, Inc.
Sector
Industry
CEO
Dipal Doshi
Website
Headquarters
Boston
Employees (FY)
159
Founded
2016
ISIN
US29384C1080
FIGI
BBG00MTSMC16
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TRDA is 12.89 USD — it has decreased by 0.46% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Entrada Therapeutics, Inc. stocks are traded under the ticker TRDA.
Entrada Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Entrada Therapeutics, Inc. has a max estimate of 22.00 USD and a min estimate of 20.00 USD.
TRDA earnings for the last quarter are 1.02 USD whereas the estimation was −0.74 USD which accounts for 238.78% surprise. Estimated earnings for the next quarter are −0.17 USD. See more details about Entrada Therapeutics, Inc. earnings.
Entrada Therapeutics, Inc. revenue for the last quarter amounts to 43.74 M USD despite the estimated figure of 9.60 M USD. In the next quarter revenue is expected to reach 23.69 M USD.
Yes, you can track Entrada Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, TRDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Entrada Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 159.00 employees. See our rating of the largest employees — is Entrada Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Entrada Therapeutics, Inc. EBITDA is −385.00 K USD, and current EBITDA margin is −0.25%. See more stats in Entrada Therapeutics, Inc. financial statements.